Literature DB >> 23962514

A standardized relative resource cost model for medical care: application to cancer control programs.

Maureen C O'Keeffe-Rosetti1, Mark C Hornbrook, Paul A Fishman, Debra P Ritzwoller, Erin M Keast, Jenny Staab, Jennifer Elston Lafata, Ramzi Salloum.   

Abstract

Medicare data represent 75% of aged and permanently disabled Medicare beneficiaries enrolled in the fee-for-service (FFS) indemnity option, but the data omit 25% of beneficiaries enrolled in Medicare Advantage health maintenance organizations (HMOs). Little research has examined how longitudinal patterns of utilization differ between HMOs and FFS. The Burden of Cancer Study developed and implemented an algorithm to assign standardized relative costs to HMO and Medicare FFS data consistently across time and place. Medicare uses 15 payment systems to reimburse FFS providers for covered services. The standardized relative resource cost algorithm (SRRCA) adapts these various payment systems to utilization data. We describe the rationale for modifications to the Medicare payment systems and discuss the implications of these modifications. We applied the SRRCA to data from four HMO sites and the linked Surveillance, Epidemiology, and End Results-Medicare data. Some modifications to Medicare payment systems were required, because data elements needed to categorize utilization were missing from both data sources. For example, data were not available to create episodes for home health services received, so we assigned costs per visit based on visit type (nurse, therapist, and aide). For inpatient utilization, we modified Medicare's payment algorithm by changing it from a flat payment per diagnosis-related group to daily rates for diagnosis-related groups to differentiate shorter versus longer stays. The SRRCA can be used in multiple managed care plans and across multiple FFS delivery systems within the United States to create consistent relative cost data for economic analyses. Prior to international use of the SRRCA, data need to be standardized.

Entities:  

Mesh:

Year:  2013        PMID: 23962514      PMCID: PMC3748000          DOI: 10.1093/jncimonographs/lgt002

Source DB:  PubMed          Journal:  J Natl Cancer Inst Monogr        ISSN: 1052-6773


  20 in total

1.  Estimating health care costs related to cancer treatment from SEER-Medicare data.

Authors:  Martin L Brown; Gerald F Riley; Nicki Schussler; Ruth Etzioni
Journal:  Med Care       Date:  2002-08       Impact factor: 2.983

2.  It's the prices, stupid: why the United States is so different from other countries.

Authors:  Gerard F Anderson; Uwe E Reinhardt; Peter S Hussey; Varduhi Petrosyan
Journal:  Health Aff (Millwood)       Date:  2003 May-Jun       Impact factor: 6.301

Review 3.  An overview of the development and refinement of the Resource-Based Relative Value Scale. The foundation for reform of U.S. physician payment.

Authors:  W C Hsiao; P Braun; D L Dunn; E R Becker; D Yntema; D K Verrilli; E Stamenovic; S P Chen
Journal:  Med Care       Date:  1992-11       Impact factor: 2.983

Review 4.  Opportunities and challenges for measuring cost, quality, and clinical effectiveness in health care.

Authors:  Paul A Fishman; Mark C Hornbrook; Richard T Meenan; Michael J Goodman
Journal:  Med Care Res Rev       Date:  2004-09       Impact factor: 3.929

5.  The challenge of conducting comparative effectiveness research in cancer: the impact of a fragmented U.S. health-care system.

Authors:  Paul A Fishman; Mark C Hornbrook; Debra P Ritzwoller; Maureen C O'Keeffe-Rosetti; Jennifer Elston Lafata; Ramzi G Salloum
Journal:  J Natl Cancer Inst Monogr       Date:  2013

6.  Assessing the implementation of physician-payment reform.

Authors:  W C Hsiao; D L Dunn; D K Verrilli
Journal:  N Engl J Med       Date:  1993-04-01       Impact factor: 91.245

7.  Hospice use among Medicare managed care and fee-for-service patients dying with cancer.

Authors:  Ellen P McCarthy; Risa B Burns; Quyen Ngo-Metzger; Roger B Davis; Russell S Phillips
Journal:  JAMA       Date:  2003-05-07       Impact factor: 56.272

8.  Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer care.

Authors:  S H Taplin; W Barlow; N Urban; M T Mandelson; D J Timlin; L Ichikawa; P Nefcy
Journal:  J Natl Cancer Inst       Date:  1995-03-15       Impact factor: 13.506

9.  Case mix use in 25 countries: a migration success but international comparisons failure.

Authors:  Francis H Roger France
Journal:  Int J Med Inform       Date:  2003-07       Impact factor: 4.046

10.  Medical expenditures for major diseases, 1995.

Authors:  T A Hodgson; A J Cohen
Journal:  Health Care Financ Rev       Date:  1999
View more
  14 in total

1.  Advancing comparative studies of patterns of care and economic outcomes in cancer: challenges and opportunities.

Authors:  K Robin Yabroff; Silvia Francisci; Angela Mariotto; Maura Mezzetti; Anna Gigli; Joseph Lipscomb
Journal:  J Natl Cancer Inst Monogr       Date:  2013

2.  Comparing cancer care, outcomes, and costs across health systems: charting the course.

Authors:  Joseph Lipscomb; K Robin Yabroff; Mark C Hornbrook; Anna Gigli; Silvia Francisci; Murray Krahn; Gemma Gatta; Annalisa Trama; Debra P Ritzwoller; Isabelle Durand-Zaleski; Ramzi Salloum; Neetu Chawla; Catia Angiolini; Emanuele Crocetti; Francesco Giusti; Stefano Guzzinati; Maura Mezzetti; Guido Miccinesi; Angela Mariotto
Journal:  J Natl Cancer Inst Monogr       Date:  2013

3.  Telephone interventions for co-morbid insomnia and osteoarthritis pain: The OsteoArthritis and Therapy for Sleep (OATS) randomized trial design.

Authors:  Susan M McCurry; Michael Von Korff; Charles M Morin; Amy Cunningham; Kenneth C Pike; Manu Thakral; Robert Wellman; Kai Yeung; Weiwei Zhu; Michael V Vitiello
Journal:  Contemp Clin Trials       Date:  2019-10-13       Impact factor: 2.226

4.  A Framework for Enhancing the Value of Research for Dissemination and Implementation.

Authors:  Gila Neta; Russell E Glasgow; Christopher R Carpenter; Jeremy M Grimshaw; Borsika A Rabin; Maria E Fernandez; Ross C Brownson
Journal:  Am J Public Health       Date:  2015-01       Impact factor: 9.308

5.  Study protocol: Using peer support to aid in prevention and treatment in prediabetes (UPSTART).

Authors:  Michele Heisler; Jeffrey Kullgren; Caroline Richardson; Shelley Stoll; Cristina Alvarado Nieves; Deanne Wiley; Tali Sedgwick; Alyce Adams; Monique Hedderson; Eileen Kim; Megan Rao; Julie A Schmittdiel
Journal:  Contemp Clin Trials       Date:  2020-06-01       Impact factor: 2.226

6.  Advanced imaging among health maintenance organization enrollees with cancer.

Authors:  Elizabeth T Loggers; Paul A Fishman; Do Peterson; Maureen O'Keeffe-Rosetti; Caprice Greenberg; Mark C Hornbrook; Lawrence H Kushi; Sarah Lowry; Arvind Ramaprasan; Edward H Wagner; Jane C Weeks; Debra P Ritzwoller
Journal:  J Oncol Pract       Date:  2014-05-20       Impact factor: 3.840

7.  Medical Care Costs for Recurrent versus De Novo Stage IV Cancer by Age at Diagnosis.

Authors:  Debra P Ritzwoller; Paul A Fishman; Matthew P Banegas; Nikki M Carroll; Maureen O'Keeffe-Rosetti; Angel M Cronin; Hajime Uno; Mark C Hornbrook; Michael J Hassett
Journal:  Health Serv Res       Date:  2018-07-24       Impact factor: 3.402

8.  Estimating the Impact of Diabetes Mellitus on Worker Productivity Using Self-Report, Electronic Health Record and Human Resource Data.

Authors:  David C Tabano; Melissa L Anderson; Debra P Ritzwoller; Arne Beck; Nikki Carroll; Paul A Fishman; David C Grossman
Journal:  J Occup Environ Med       Date:  2018-11       Impact factor: 2.162

9.  Health Care Costs of Alzheimer's and Related Dementias Within a Medicare Managed Care Provider.

Authors:  Paul A Fishman; Lindsay White; Bailey Ingraham; Sungchul Park; Eric B Larson; Paul Crane; Norma B Coe
Journal:  Med Care       Date:  2020-09       Impact factor: 2.983

10.  Cost-Effectiveness of a Web-Based Program for Residual Depressive Symptoms: Mindful Mood Balance.

Authors:  Jennifer M Boggs; Debra P Ritzwoller; Arne Beck; Sona Dimidjian; Zindel V Segal
Journal:  Psychiatr Serv       Date:  2021-07-29       Impact factor: 3.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.